

● PRINTER RUSH ●

(PTO ASSISTANCE)

Application :	<u>10062879</u>	Examiner :	<u>Tiang</u>	GAU :	<u>11416</u>
From :	<u>MW</u>	Location :	<u>IDC</u> FMF FDC	Date :	<u>8/8/05</u>
Tracking #:			<u>06110407</u>	Week Date: <u>5/3/05</u>	

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449	_____	<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS	_____	<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM	_____	<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW	_____	<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW	_____	<input type="checkbox"/> Other
<input type="checkbox"/> DRW	_____	
<input type="checkbox"/> OATH	_____	
<input type="checkbox"/> 312	_____	
<input checked="" type="checkbox"/> SPEC	<u>9-1-2004</u>	

[RUSH] MESSAGE: _____

① There is illegible data within the amendments dated 9-1-2004 due to lines going through the text. Please advise.

Thanks.

[XRUSH] RESPONSE: _____

Completed

8-23-05

INITIALS: REB

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.
REV 10/04

Potassium

Amendments to the Specification

Please add the following new paragraph on page 1 after the title "Human Potassium Channel Polynucleotides and Polypeptides and Uses Thereof":

09/178109

The present application is a division of U.S. Patent Application Serial No. 09/118,109, filed October 23, 1998, now U.S. Patent No. 6,395,477.

Please replace the paragraph starting with "Figure 1A" on page 4 with the following amended paragraph:

following

~~Figure 1A. Amino acid sequence of human Kv4.3 long and alignment with rat Kv4.3 long, rat Kv4.2, and mouse Kv4.1. The S1-S6 and P domains are overlined. The three amino acid difference between human and rat Kv4.3 are denoted with down arrows (153, 501, 687). The 19 amino acid alternative splice site is indicated with a double underline (444-512). The serines (505, 509) are putative PKC consensus sites with the insert region Human Multi-Tissue Northern blot, probed with human Kv4.3.~~

Please replace the paragraph starting with "Figure 1B" on page 4 with the following amended paragraph:

following

~~Figure 1B. (A) Human Multi-Tissue Northern blot, probed with human Kv4.3 (B) b-actin control (C) RT-PCR showing tissue distribution of hKv4.3 splice variants (short and long forms) for the corresponding tissue set.~~

Please add the following new paragraph on page 4 after the paragraph starting with "Figure 1B":

starting

~~Figure 1C. RT-PCR showing tissue distribution of hKv4.3 splice variants (short and long forms) for the corresponding tissue set.~~

of short

Please replace the paragraph starting with "FIG. 1A shows" on page 12 with the following amended paragraph:

with

Response to Office Action--page 2 of 10

~~FIG. 1A shows the~~ The complete amino acid sequence of hKv4.3 long with the ~~insert~~ region ^{insert} highlighted, ~~along with an alignment is aligned~~ with rat Kv4.3 (Imaizumi et al. 1997), rat Kv4.2 (Baldwin et al. 1991), and mouse Kv4.1 (Pak et al. 1991). When compared to the ^{compared} previously reported rat clones of Kv4.3 (Rudy et al., McKinnon, and Imaizumi), the two Imaizumi variants of the hKv4.3 clones are 91% homologous at the nucleotide level and ~~diff~~ ^{differ} by only three amino acids (~~FIG. 1A arrows~~).

Please replace the paragraph starting with "In Rat" on page 17 with the following amended following paragraph:

In rat, evidence of two isoforms of Kv4.3 differing by a +/-57 base pair insert. In order to see ^{In} if a shorter form of hKv4.3 existed in human tissue we synthesized primers that flanked the ^{that} 57 bp insert in the long form of hKv4.3. These generated products of either 137 bp or 180 ²³⁷ bp, reflecting the presence or absence of the 57 bp insertion. Both forms ~~were~~ ^{were} identified in human brain (~~FIG. 2B~~ ^{FIG. 1C}). To clone the shorter version a second ~~set~~ ^{set} of flanking primers were synthesized and used to generate two bands (767 bp and 710 bp). The shorter ^{bp} band was cloned and sequenced to confirm the absence of the 57 bp region. ^{BglIII} ~~H~~ and SacI sites flank this region and were used with the 710 bp product to directionally ~~clone~~ ^{clone} the shorter fragment of hKv4.3 into the corresponding region of full length hKv4.3.

Response to Office Action--page 3 of 10

8. (canceled)

9. (canceled)

10. (currently amended) A non-naturally occurring Kv4.3 polypeptide ~~comprising an amino acid~~ comprising the amino acid sequence of SEQ ID NO: 2.

11. (withdrawn) An oligonucleotide which encodes an antisense sequence ~~complementary to~~ complementary to a portion of a human Kv4.3 potassium channel sequence of SEQ ID NO: 1 or ~~SEQ ID NO: 3~~ SEQ ID NO: 3 and which inhibits expression of the human Kv4.3 gene.

12. (withdrawn) An antibody immunospecific for the human Kv4.3 polypeptide of claim 9. of

13. (withdrawn) A method for diagnosing a disease characterized by aberrant expression of human potassium channel Kv4.3 polypeptide of claim 9 comprising (a) incubating a sample incubating indicative of the aberrant expression of the human polypeptide with a reagent comprising a reagent polypeptide comprising a region at least 90% identical to the amino acid sequence of SEQ ID sequence NO: 2 or SEQ ID NO: 4 under conditions effective for specific binding of said reagent to said said reagent human polypeptide; and (b) determining the binding of said reagent to said peptide in the said sample.

14. (withdrawn) A diagnostic process comprising analyzing for the presence of a presence polynucleotide of claim 1 in a sample derived from a host.

15. (withdrawn) A method for identifying compounds which modulates the activity or modulates expression of a human Kv4.3 polypeptide of claim 9 comprising (a) incubating a sample incubating comprising Kv4.3 polypeptide in a test medium containing said test compound and a reagent compound comprising a polypeptide comprising a region at least 90% identical to the amino acid to sequence of SEQ ID NO: 2 or SEQ ID NO: 4 under conditions effective for specific binding for of said reagent to said Kv4.3 peptide; (b) comparing the binding of said reagent to said said peptide in the sample in the presence and absence of said test compound; and (c) relating the and difference between the binding in step (b) to the test compound regulating the activity of the the Kv4.3 polypeptide.

Response to Office Action—page 5 of 10

16. (withdrawn) A transgenic or chimeric animal comprising the polynucleotide of claim 1. of
17. (canceled)
18. (canceled)
19. (currently amended) A non-naturally occurring Kv4.3 polypeptide comprising an amino acid comprising the amino acid sequence of SEQ ID NO: 4.
20. (canceled)
21. (canceled)
22. (new) A recombinantly-produced polypeptide comprising SEQ ID NO:1 or SEQ ID NO:2
23. (new) A purified or chemically-synthesized polypeptide comprising SEQ ID NO:2 or SEQ ID NO:4.
24. (new) An isolated polypeptide comprising SEQ ID NO:2 or SEQ ID NO:4
25. (new) A Kv4.3 potassium channel produced by expressing from a recombinant vector comprising the nucleotide sequence depicted in SEQ ID NO:1 or SEQ ID NO:3, wherein said nucleotide sequence is operatively linked to one or more expression control sequences.
- recombinant
NO:3,
sequences
- NO:4